BidaskClub upgraded shares of Heska (NASDAQ:HSKA) from a hold rating to a buy rating in a research note released on Wednesday.

A number of other equities analysts have also weighed in on HSKA. ValuEngine upgraded Heska from a hold rating to a buy rating in a research report on Monday, July 2nd. Zacks Investment Research upgraded Heska from a strong sell rating to a hold rating in a research report on Wednesday, July 18th. Benchmark started coverage on Heska in a research report on Thursday, July 19th. They issued a buy rating and a $120.00 price target for the company. Finally, TheStreet lowered Heska from a b rating to a c+ rating in a research report on Monday, August 20th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. Heska has a consensus rating of Buy and a consensus price target of $107.50.

Shares of NASDAQ:HSKA traded down $2.30 during midday trading on Wednesday, reaching $99.68. The company had a trading volume of 107,743 shares, compared to its average volume of 42,403. Heska has a 1-year low of $56.59 and a 1-year high of $114.50. The firm has a market capitalization of $747.38 million, a price-to-earnings ratio of 48.15 and a beta of 0.50.

Heska (NASDAQ:HSKA) last released its quarterly earnings results on Tuesday, August 7th. The medical research company reported $0.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.17 by $0.07. Heska had a return on equity of 11.49% and a net margin of 4.67%. The business had revenue of $29.66 million during the quarter, compared to analyst estimates of $30.19 million. On average, analysts anticipate that Heska will post 1.67 EPS for the current year.

In related news, EVP Steven M. Eyl sold 33,351 shares of the stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $98.49, for a total value of $3,284,739.99. Following the completion of the sale, the executive vice president now directly owns 15,401 shares of the company’s stock, valued at approximately $1,516,844.49. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Steven M. Eyl sold 1,051 shares of the stock in a transaction dated Friday, August 10th. The stock was sold at an average price of $98.00, for a total value of $102,998.00. Following the completion of the sale, the executive vice president now directly owns 15,401 shares of the company’s stock, valued at $1,509,298. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,828 shares of company stock valued at $5,854,060. Company insiders own 14.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Piedmont Investment Advisors LLC purchased a new stake in Heska in the 2nd quarter worth about $162,000. SG Americas Securities LLC purchased a new stake in Heska in the 2nd quarter worth about $191,000. Paloma Partners Management Co purchased a new stake in Heska in the 2nd quarter worth about $228,000. Macquarie Group Ltd. purchased a new stake in Heska in the 2nd quarter worth about $234,000. Finally, Raymond James Trust N.A. purchased a new stake in Heska in the 2nd quarter worth about $240,000. 88.92% of the stock is owned by hedge funds and other institutional investors.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Read More: Stock Symbols, CUSIP and Other Stock Identifiers

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.